Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Shares Outstanding (Weighted Average) (2018 - 2025)

10x Genomics' Shares Outstanding (Weighted Average) history spans 8 years, with the latest figure at $124.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 3.57% year-over-year to $124.7 million; the TTM value through Dec 2025 reached $124.7 million, up 3.57%, while the annual FY2025 figure was $124.7 million, 3.57% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $124.7 million at 10x Genomics, down from $125.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $125.5 million in Q3 2025 and bottomed at $108.7 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $116.4 million (2023), against an average of $116.8 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) increased 12.27% in 2021 before it grew 2.26% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $110.3 million in 2021, then grew by 3.18% to $113.9 million in 2022, then grew by 2.9% to $117.2 million in 2023, then increased by 2.81% to $120.5 million in 2024, then rose by 3.57% to $124.7 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Shares Outstanding (Weighted Average) are $124.7 million (Q4 2025), $125.5 million (Q3 2025), and $123.2 million (Q2 2025).